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Neurologic complications of HTLV-1: a review.
Complicações neurológicas do HTLV: uma revisão HTLV-1
Abelardo Q-C Araujo1
ABSTRACT
The human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus 
that infects about 20 million people worldwide and causes immune-
-mediated diseases of the nervous system. The classical neurological 
presentation of HTLV-1 infection is the so-called HTLV-1-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP). However, HAM/
TSP is not the only neurological outcome that can result from HTLV-1 
infection. In this Review it is made an update on the many aspects of 
this important neurological condition, the HTLV-1 neurological com-
plex.
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RESUMO
O vírus linfotrópico de células T humanas tipo 1 (HTLV-1) é um retro-
vírus que infecta cerca de 20 milhões de pessoas em todo o mundo e 
causa doenças imunomediadas do sistema nervoso. A apresentação 
neurológica clássica da infecção pelo HTLV-1 é a chamada parapare-
sia espástica tropical / mielopatia associada ao HTLV-1 (HAM/TSP). 
HAM / TSP,no entanto, não é o único desfecho neurológico que pode 
resultar da infecção pelo HTLV-1. Nesta revisão, é feita uma atualiza-
ção sobre vários aspectos desta importante condição neurológica, o 
complexo neurológico do HTLV-1.
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INTRODUCTION
The human T cell lymphotropic virus type 1 
(HTLV-1)was the first human retrovirus to be discovered 
and belongs to the Retroviridae family, the Orthoretrovi-
rinae subfamily and to the deltaretrovirus genus1. HTLV-
1 preferentially infects CD4+CCR4+ effector/memory T 
cellsin vivo2. 
HTLV-1is the causative agent of a variety of di-
seases including adult T-cell leukemia/lymphoma (ATLL)3 
and the HTLV-1-associated myelopathy/tropical spastic 
paraparesis (HAM/TSP)4. ATLL is due to a neoplastic clo-
nal growth of HTLV-1-infected CD4 positive T-cells and is 
characterized by unique clinical features including hyper-
calcemia and severe organ infiltration of leukemic cells. 
HAM/TSP is an immune-mediated disease of the central 
nervous system (CNS) but the precise mechanism for di-
sease development is still a matter of debate5. 
EPIDEMIOLOGY
The most endemic regions to HTLV-1 are the 
Southwestern part of Japan, sub-Saharan Africa, South 
America, the Caribbean area, and some foci in the Middle 
East and Australo-Melanesia. HTLV-1 can be transmitted 
through breastfeeding, sexual intercourse, and contact with 
contaminated cellular blood products. The HTLV-1 preva-
lence increases gradually with age, especially among wo-
men. Nowadays it is estimated the total number of HTLV-
1 carriers to vary between 10-20 million individuals6. 
In contrast to HIV-1 infection, where most patien-
ts end up with AIDS, only 2%-3% of infected persons de-
velop ATLL and other 0.25%–3.8% develop HAM/TSP, 
while the majority of infected individuals remain lifelong 
asymptomatic carriers (ACs).Apparently host and virolo-
gical factors play a role in the neurological outcome once 
an individual becomes infected5,6.
PATHOPHYSIOLOGY
To date the best predictor of becoming ill is a high 
HTLV-1 proviral load (PVL), in other words, the percen-
tage of peripheral blood mononuclear cells (PBMCs) that 
carry the provirus. In Japanese studies the median PVL 
was more than 10 times higher in HAM/TSP patients than 
in asymptomatic carriers (ACs)7. Studies from the Cari-
bbean, South America, and the Middle East replicated the-
se findings. Apparently genetic factors such as the human 
leukocyte antigen (HLA) genotype are related to the high 
PVL in HAM/TSP patients and genetic relatives. In chro-
nic HTLV-1 infection about 90–95% of the PVL is carried 
by CD4+ T cells and 5–10% by CD8+ T cells5. 
HAM/TSP is characterized by an over-stimula-
tion of the immunologic compartment, including increa-
sed expression of a repertoire of inflammatory cytokines 
and chemokines, and an increase in the number of highly 
activated circulating CD8+ T cells directed against the 
Tax11-19 viral epitope in both peripheral blood (PB) and 
cerebrospinal fluid (CSF)5. 
 The real mechanisms by which HTLV-1 induces 
neurological diseases remain unknown so far. The main 
hypothesis to explain HAM/TSP neuropathogenesis is the 
so-calledBystander damage. It suggests that the presence 
of interferon-gamma-secreting HTLV-1- infected CD4+ 
T cells and their recognition by virally specific cytoto-
xic T CD8 CTL in the CNS induce microglia to secrete 
some cytokines, such as TNF- alpha, which may be toxic 
for myelin. Both anatomically determined hemodynamic 
conditions and adhesion molecule-mediated interactions 
between circulating infected T cells and endothelial ce-
lls may contribute to the localization of the main lesions. 
Following an induction of the HTLV-1 antigens on the sur-
face of infected T cells in CNS compartment, expansion 
of the responses of immunocompetent T cells against the 
viral proteins may result in CNS tissue damage that may 
be mediated by released cytokines. More recently some 
investigators advocated the possibility of the existence of a 
continuous positive feedback loop via astrocytes that wou-
ld maintain a state of chronic inflammation of the spinal 
cord in HAM/TSP. Accordingly, HTLV-1-infected cells in 
the CNS would produce interferon-gamma that would in-
duce astrocytes to secrete the chemokine CXCL10, which 
would be able to recruit more infected cells to the area via 
the chemokine receptor CXCR3, constituting a T helper 
type 1-centric positive feedback loop that would result in a 
state of chronic inflammation8.
In necropsy cases of Japanese HAM/TSP the spi-
nal cord shows symmetrical atrophy especially of the tho-
racic cord proportionally to the severity of neurological 
deficits. Infiltration of mononuclear cells and degeneration 
of both myelin and axons are the essential microscopical 
findings of cases with relatively short clinical course of 
the disease. Inflammatory lesions are most severe in the 
middle-lower thoracic spinal cords and extend throughout 
the entire spinal cord. Similar but milder lesions are seen 
scattered in the brain. In patients with a more prolonged 
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clinical history, the spinal cord shows a monotonous dege-
neration and gliosis with a few inflammatory cells in the 
perivascular areas. Fibrous thickening of the vessel walls 
and pia mater are frequently noted. These findings suggest 
a preceded inflammatory process in such areas. Degenera-
tion of the spinal cord white matter is symmetric and diffu-
se but more severe at the anterio-lateral column and inner 
portion of the posterior column where the inflammatory 
lesions are accentuated in the active-chronic phase. There 
are no focal demyelinating plaques. HTLV-1 proviral DNA 
can be detected in extracted DNA from affected spinal cord 
in HAM/TSP by PCR. The amount tends to decrease with 
the disease progression and this decline is paralleled with 
the decrease of CD4+ T-cell numbers9. 
Some authors outside Japan put less importance 
on the inflammatory component of these lesions. They 
speculate that in their autopsy cases the neuraxisis affected 
in a more systemic axial fashion as seen in neurodegenera-
tive diseases, and the lesions did not seem to be secondary 
to vascular or inflammatory abnormalities, as proposed by 
the Japanese10. 
Cases with other neurological manifestations of 
HTLV-1 infection who have been submitted to pathologi-
cal examination showed a variety of findings such as va-
rious degrees of inflammatory changes with necrotic and 
degenerating muscle fibers and focal invasion of HTLV-1 
infected CD4+ cells (mainly) in HTLV-1-associated myo-
sitis; anterior horn cell loss with surrounding infiltration 
of CD8+ lymphocytes, gliosis, axonal and myelin loss of 
the pyramidal tracts in all spinal cord levels, and thickened 
and infiltrated leptomeninges in those ALS-like cases; and 
a combination of both demyelination/remyelination and 
axonal degeneration/regeneration or, less often, the pre-
sence of inflammatory infiltrates in the peripheral nerves 
in those patients with polyneuropathy5.
CLINICAL FEATURES OF THE HTLV-1-ASSOCIATED 
NEUROLOGICAL COMPLEX11
- HAM/TSP12: is a neurological condition still de-
fined clinically and serologically in accordance with gui-
delines proposed by a W.H.O. panel of experts in 1988. 
These guidelines, although still largely employed, have 
some important shortcomings. Several vague terms are 
used frequently and the criteria are far from being strin-
gent, encompassing many syndromes into a single one. 
This led to a proposal of new diagnostic guidelines that 
classified the disease according to different sublevels of 
ascertainment (Table 1)13. 
HAM/TSP is a slowly progressive disease. Some 
large prospective studies show thatpatients progressed 
from disease onset to wheelchair confinement over a me-
dian of 21 years14,15.
Although HAM/TSP is certainly the tip of the ice-
berg of the HTLV-1 associated neurological complex other 
neurological syndromes can be found in HTLV-1 positive 
individuals without myelopathy or, more often, in asso-
ciation with HAM/TSP. This implies that the neurologi-
cal spectrum of HTLV-1 might be broader than previously 
thought.
-HTLV-1 ASSOCIATED POLYMYOSITIS (HAPM)16,17: 
Although isolated HAPm has been described, most 
published cases are associated with HAM/TSP.HAPm is an 
important diagnosis to bear in mind if patients with HAM/
TSP start to develop a new pattern of muscular weakness 
(more proximal), myalgias, and increased creatine kinase 
(CK) levels. Compared to idiopathic polymyositis,HAPm 
follows a more protracted course and is particularly resis-
tant to steroids.
- HTLV-1 ASSOCIATED POLYNEUROPATHY (HAPN)18–20: 
Peripheral neuropathies have been consistently 
found in association with HAM/TSP. The clinical picture 
is ofparesthesias, burning sensations, and abnormal super-
ficial sensation distally in a stock and glove distribution, 
generally associated with abolished ankle jerks. Although 
in most cases the peripheral nerve involvement is associa-
ted with HAM/TSP they can also be found in isolation, wi-
thout any accompanying sign of spinal cord involvement. 
When present, these isolated HAPn manifest mostly as a 
predominantly sensory axonal polyneuropathy. 
- HTLV-1 ASSOCIATED DYSAUTONOMIA (HAD)21,22: 
Autonomic disturbances are always associated 
with HAM/TSP and so far have never been described 
in isolation. It is characterized by impairment of cardio-
vascular and sweat control, and clearly indicates a major 
dysfunction of the sympathetic nervous system. Postural 
hypotension is a common feature of HAM/TSP and shou-
ld always be investigated and treated symptomatically. 
Perhaps the dysautonomia is more frequent than previou-
sly suggested, and in some cases may be severe enough to 
warrant specific treatment. Cardiovascular autonomic dys-
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function in HAM/TSP patients is mainly associated with 
cardiac sympathetic efferent abnormalities in the upper 
thoracic segments.
- AMYOTROPHIC LATERAL SCLEROSIS-LIKE 
SYNDROME ASSOCIATED WITH HTLV-1 (ALS-
HTLV)23–25:
Amyotrophic lateral sclerosis (ALS) is a progres-
sive, invariably fatal neurologic disorder resulting from 
upper and lower motor neuron degeneration, which typi-
cally develops during the sixth or seventh decade of life, 
and is diagnosed based on standard clinical criteria. Its 
underlying cause remains undetermined. The disease may 
occur with increased frequency within certain families, of-
ten in association with specific genomic mutations, while 
some sporadic cases have been linked to environmental 
toxins or trauma. Another possibility, first proposed in the 
1970s, is that retroviruses play a role in pathogenesis. 
Amyotrophic lateral sclerosis-like pictures have 
been occasionally described as a sole manifestation of 
HTLV-1 infection. The main difference between these pa-
tients and the typical HTLV-1 negative ALS cases is the 
longer evolution and slower progression of HTLV-1 infec-
ted individuals.
-CHRONIC DIFUSE ENCEPHALOMYELOPATHY, 
ENCEPHALITIS AND COGNITIVE DEFICITS:
Diffusebrain white matter MRI abnormalities, 
reflecting a chronic perivascular inflammation with pro-
gressive gliosis can explain the mild cognitive disturbance 
reported in some HTLV-1-infected individuals, with psy-
chomotor slowing and deficits in verbal and visual me-
mory, attention, and visuomotor abilities26. Imaging and 
autopsy studies IN HAM/TSP also demonstrate brain in-
flammation. In general, this is subclinical. More recently, 
patients with reduced consciousness, fever/hypothermia, 
headaches, seizures, and focal neurological signs have 
been described in association with HTLV-1 infection. His-
topathology showed perivascular predominantly CD8+ 
lymphocytic infiltrates in the brain27. 
INVESTIGATIONS
A variety of systemic laboratory abnormalities can 
be found in patients with HAM/TSP, such as the presence 
of “flowers cells” (atypical lymphocytes with petal sha-
pe nuclei, typical of ATLL), hypergammaglobulinemia, 
increased proportion of CD4+ to CD8+ cells, presence 
of autoantibodies and false-positive serologic tests, such 
as VDRL and Lyme serology. A higher PVL in the blood 
seems to be able to distinguish HAM/TSP from those 
asymptomatic carriers, as well as those individuals with a 
more rapid disease progression5.
The CSF may be normal or reveal a small/modera-
te mononuclear pleocytosisalong with amodestly elevated 
protein content. In addition, oligoclonalIgG bands, increa-
sed levels of cytokines (neopterin, TNF-α, IL-6 and IL-γ), 
and increased intrathecal antibody synthesis specific for 
HTLV-1 antigens have also been described. Some authors 
have advocated the use of PVL measurement in the CSF 
as a diagnostic method to help in the definition of HAM/
TSP15,28, althought there is no agreement about that29. 
Accordingly, the percentage of HTLV-1-infected cells in 
the CSF cells and the CSF/PBMC HTLV-1PVL ratio are 
always >10% and >1, respectively, in patients with HAM/
TSP in contrast to <10% and <1, respectively, in asympto-
matic carriers. 
As mentioned, the PVL is higher in the blood of 
HAM/TSP than in asymptomatic carriers. PVL values vary 
widely between individuals, but are relatively constant wi-
thin individuals.
Cerebral white matter lesions and spinal cord ab-
normalities have been frequently observed in HAM/TSP. 
Sometimes, early in the course of the myelopathy, one can 
find spinal cord edema, reflecting an active inflammatory 
process. As the disease progresses the spinal cord becomes 
progressively atrophic30. 
DIFFERENTIAL DIAGNOSIS
HAM/TSP can be occasionally mistaken for other 
neurological conditions such as the “progressive” spinal 
form of multiple sclerosis, the vacuolar myelopathy of 
AIDS, sporadic cases of familial spastic paraparesis, pri-
mary lateral sclerosis, some slowly progressive spinal cord 
compressions, vitamin B12 or copper deficiency, idiopa-
thic transverse myelitis, Lyme disease, and neurosyphilis31. 
Most of these conditions can be ruled out by an 
initial screening with a brain and spinal magnetic resonan-
ce imaging (MRI), CSF examination, and specific blood 
tests. 
MANAGEMENT AND TREATMENT
HAM/TSP is a highly incapacitating myelopathy, 
but clinical trials of specificdrugs to treat it are lacking. 
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Oral or intravenous corticosteroids are still the mainstay 
of HAM/TSP treatment,particularly in the initial phase of 
the disease, when inflammation is more prominentthan 
demyelination and gliosis32. Motor disability, pain, and 
urinary dysfunction may beameliorated with steroids,but 
improvement is usually not sustained in mostof the patien-
ts5.
Since HAM/TSP is associated with a high HTLV-
1 PVL, reducing this load could treat or even prevent 
disease. However, despite in vitro evidence that certain 
nucleoside/nucleotide analogue reversetranscriptase inhi-
bitors (NRTIs) are active against HTLV-1, in vivo results 
have been disappointing showing no clinical improvement 
or reduction of the PVL33. Valproic acidarose as a poten-
tial treatment for HAM/TSP based on evidences showing 
thatthis drug can activate viral gene expression and expose 
virus-infected cells to theimmune system, leading to a re-
duction of the PVL. Despite these theoretical advantages 
the drug resulted ineffective to improve motor and other 
disabilities34. Other drugs such as interferon-alpha,cyclos-
porin A, methotrexate, pentoxifylline, azathioprine, and 
danazolmay betried if steroids fail or cannot be tolerated, 
but their use should be balanced in terms of their indivi-
dual risk-benefit profile5. 
Symptomatic treatment employing drugs and phy-
sical therapy to alleviate pain - which strongly correlates 
with a low quality of life of these individuals-, spasticity 
and to improve bladder control, are nowadays the mains-
tay in the treatment of HAM/TSP35.
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